Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
about
Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancerThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009Early-Stage Breast Cancer in the Elderly: Confronting an Old Clinical ProblemNuclear cyclin B1 in human breast carcinoma as a potent prognostic factorFactors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.A Normalized Tree Index for identification of correlated clinical parameters in microarray experimentsThe role of poverty rate and racial distribution in the geographic clustering of breast cancer survival among older women: a geographic and multilevel analysis.Using clinical trial data to tailor adjuvant treatments for individual patients.Merging microarray data from separate breast cancer studies provides a robust prognostic test.A systems approach to clinical oncology: focus on breast cancer.Proteomics of breast cancer: principles and potential clinical applications.Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastasesNuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinomaLymph vascular invasion in invasive mammary carcinomas identified by the endothelial lymphatic marker D2-40 is associated with other indicators of poor prognosisExpression profiling with RNA from formalin-fixed, paraffin-embedded materialSequencing chemotherapy and radiotherapy in locoregional advanced breast cancer patients after mastectomy - a retrospective analysis.Gene expression variation between distinct areas of breast cancer measured from paraffin-embedded tissue cores.Immunostaining with D2-40 improves evaluation of lymphovascular invasion, but may not predict sentinel lymph node status in early breast cancerLow expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer.Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases.Pathway-BasedFeature Selection Algorithm for Cancer Microarray Data.Spectrum of very early breast cancer in a setting without organised screening.Incidence of chemotherapy-induced amenorrhea associated with epirubicin, docetaxel and navelbine in younger breast cancer patients.Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.Obesity and Prognostic Variables in Colombian Breast Cancer Patients: A Cross-Sectional Study.Detection of serum VEGF and MMP-9 levels by Luminex multiplexed assays in patients with breast infiltrative ductal carcinomaMethylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis.Significance of immunohistochemistry in breast cancerA gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cellsBreast Cancer in Low and Middle Income Countries: How Can Guidelines Best Be Disseminated and Implemented?Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment.High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis.Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis.Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PETThe relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancerMedical treatment of early breast cancer. I: adjuvant treatment.Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI studyMedical treatment of early breast cancer. III: chemotherapy.Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer
P2860
Q24652752-416AFDA2-344C-4C56-9A8C-BBD101CE7924Q24657145-728778E2-7562-46A9-B8F3-48F8714804D1Q26782584-DAE0E413-22F1-4B18-B447-80F171A52C08Q28292835-B7D3AA8E-7BE5-4E7E-AB6F-4269F382AC00Q30313653-37293851-6EE1-4778-B734-74FC3C240ED3Q30476946-2E5AA7B2-C576-4006-9817-70BE5867A306Q30489541-1F112A42-9CF1-4D47-8A21-8A5146C052EDQ31122593-AC1919BE-9E1C-4E05-B6A3-9CDB4279579BQ31147871-8E076CC8-B28B-46E5-97DE-2D78E4FA4683Q33238889-719F6B49-62A9-401C-8D70-216B3D769382Q33245053-06D23C0F-B5F7-441D-BA8C-DE9EAA04F603Q33264119-21165F23-8CE2-43F3-9D3F-0E91E447B651Q33303620-37CF56D5-8250-48F3-96CE-2646B53AB138Q33321717-3AD5C9A7-8BEF-4620-8AF3-E60AA0DD22A1Q33329308-F29DD998-9445-409E-B359-106EF3AE40ACQ33330481-B1E0EA7B-BC3E-4CFD-9B6A-093E6215EF93Q33387042-8A96CFBF-C00F-48C5-9858-404344AF83E6Q33428339-102176CA-B143-45E2-9DFF-1EB16E241F62Q33484404-17828CDD-AE75-4C77-8CDB-FFBD1E676563Q33535173-B273858A-BF02-4EB0-9E63-C9936A541585Q33537191-1D206A0E-4726-416A-96C2-ED20FEF6B10DQ33555289-62C3745E-D251-4118-87C2-66B8BAF27F41Q33601886-B30730F2-FC48-4672-ACFF-22056333F280Q33629626-627920E3-7887-4C63-B226-B841F4717E04Q33747941-56B6C9F5-33E5-49B1-A437-3E10FBAEB327Q33769718-4CF1259A-7620-4916-BA71-4039E7D9A1C7Q33778433-3B53330B-BF16-4D04-9F06-601A8B779074Q34023682-8D880B4A-3A85-40A7-911F-C33E56AED05BQ34029272-D2734FED-1767-4BF3-85B0-CF7DB058D89CQ34048154-58099FDE-EED3-42D0-9379-075EA209D4A5Q34095867-BAF7040F-2457-4339-A41E-850AAC0789F1Q34114155-8FA11851-3305-46C0-88D6-64A5CF324435Q34200900-B1C30523-F7E3-4E4A-ACAD-7BA737CAD9F6Q34206647-98236544-D94F-4D5A-AB8C-AC27DCD6DC57Q34235986-038627F2-93E3-4F1A-8B57-B64144272F95Q34245787-7FF8B602-6BBD-48CC-AA4A-52AE1CAA052CQ34248760-C8931E9F-ADBC-4C71-84C4-B5D0CC79DF3BQ34251780-8E04EA34-8FB2-4969-97AB-4E009E993D52Q34276260-5E1E8F66-329C-4721-9152-23E98783A037Q34284302-FFE10755-08FC-440E-AE05-3417F155EA60
P2860
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Meeting highlights: internatio ...... y of early breast cancer 2005.
@ast
Meeting highlights: internatio ...... y of early breast cancer 2005.
@en
type
label
Meeting highlights: internatio ...... y of early breast cancer 2005.
@ast
Meeting highlights: internatio ...... y of early breast cancer 2005.
@en
prefLabel
Meeting highlights: internatio ...... y of early breast cancer 2005.
@ast
Meeting highlights: internatio ...... y of early breast cancer 2005.
@en
P2093
P356
P1433
P1476
Meeting highlights: internatio ...... y of early breast cancer 2005.
@en
P2093
A Goldhirsch
A S Coates
B Thürlimann
Panel members
R D Gelber
P2860
P304
P356
10.1093/ANNONC/MDI326
P577
2005-09-07T00:00:00Z